Major Depressive Disorder
📧 Sign up to get email alerts when something new happens for Major Depressive Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2014-06-30FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for venlafaxine hydrochloride from Teva Pharmaceuticals USA, Inc., marking an approval action un…
-
CLINICAL_TRIALS trial_result · 2014-06-27Clinical Trial Update: Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment [Phase 4]
Phase 4 trial assessing whether escitalopram helps prevent or reduce depressive symptoms in people receiving interleukin-2 treatment.
-
CLINICAL_TRIALS trial_result · 2014-06-27Clinical Trial Update: Effects of a Telephone Based Peer Support to Reduce Depressive Symptoms and Improve Social Support in Women With CHD [NA]
This trial update reports a completed study evaluating telephone-based peer support to reduce depressive symptoms and improve social support…
-
CLINICAL_TRIALS trial_result · 2014-06-27Clinical Trial Update: Sertraline for Preventing Post-stroke Depression and Improving Rehabilitation Outcomes [Phase 4]
This is a Phase 4 clinical trial update on sertraline intended to prevent post-stroke depression and improve rehabilitation outcomes, which …
-
CLINICAL_TRIALS trial_result · 2014-06-27Clinical Trial Update: Activation of Young Men - Population-Based Randomised Controlled Trial [NA]
A population-based randomized controlled trial evaluating an activation program for young men, with outcomes including obesity, well-being, …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2014-06-26FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Dr. Reddy's Laboratories Limited)
FDA approves a supplemental application for venlafaxine hydrochloride from Dr. Reddy's Laboratories Limited.
-
FDA approval · 2014-06-26FDA Approved: VENLAFAXINE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
The FDA approved a supplemental application for venlafaxine submitted by Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.
-
CLINICAL_TRIALS trial_result · 2014-06-26Clinical Trial Update: Online Self-help for Depressed Patients Awaiting Psychotherapy [NA]
A clinical trial evaluating online self-help for patients with Major Depressive Disorder awaiting psychotherapy was terminated.
-
FDA approval · 2014-06-25FDA Approved: TRAZODONE HYDROCHLORIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approves a supplemental application for trazodone hydrochloride from Sun Pharmaceutical Industries, Inc.
-
CLINICAL_TRIALS trial_result · 2014-06-25Clinical Trial Update: Cognitive Behavioral Therapy for the Treatment of Seasonal Affective Disorder (SAD) [Phase 1]
Phase 1 trial evaluating Cognitive Behavioral Therapy for Seasonal Affective Disorder; the study completed and results were posted.
-
CLINICAL_TRIALS trial_result · 2014-06-19Clinical Trial Update: Cognitive Training to Improve Work Outcomes in Severe Mental Illness [Phase 2]
A Phase 2 clinical trial evaluating cognitive training to improve work outcomes in people with schizophrenia, bipolar disorder, or major dep…
-
FDA approval · 2014-06-18FDA Approved: VENLAFAXINE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for Venlafaxine hydrochloride from Aurobindo Pharma Limited.
-
CLINICAL_TRIALS trial_result · 2014-06-18Clinical Trial Update: Efficacy and Safety Study of a Combination Product [Drug:BCI-024 (Buspirone) and Drug:BCI-049 (Melatonin)] to Treat Major Depressive Disorder (MDD) [Phase 2]
Phase 2 trial results for the combination of BCI-024 (buspirone) and BCI-049 (melatonin) in major depressive disorder have been completed. T…
-
CLINICAL_TRIALS trial_result · 2014-06-18Clinical Trial Update: Inflammation-Induced Depressed Mood: The Role of Social Neurocognitive Mechanisms [EARLY_Phase 1]
The document reports on a Phase 1 trial exploring the role of inflammation in depressed mood and social neurocognitive mechanisms. The study…
-
CLINICAL_TRIALS trial_result · 2014-06-18Clinical Trial Update: A Multiple Ascending Oral Dose Evaluation of the Safety, Tolerability, and Pharmacokinetics of DSP-1053 and Its Metabolites in Healthy Subjects and in Subjects With Major Depressive Disorder [Phase 1]
Phase 1 multiple ascending dose study evaluating safety, tolerability, and pharmacokinetics of DSP-1053 and its metabolites in healthy subje…
-
FDA approval · 2014-06-17FDA Approved: VENLAFAXINE — Supplemental Application (BluePoint Laboratories)
FDA approved a supplemental application for venlafaxine from BluePoint Laboratories under ANDA077653. This action authorizes a generic versi…
-
CLINICAL_TRIALS withdrawal · 2014-06-17Clinical Trial Update: Cipralex in Treatment of Depressive Symptoms and Chronic Back Pain [Phase 4]
The Phase 4 clinical trial evaluating Cipralex (escitalopram) for depressive symptoms and chronic low back pain has been withdrawn.
-
FDA approval · 2014-06-11FDA Approved: DULOXETINE DELAYED-RELEASE — Original Application (Breckenridge Pharmaceutical, Inc.)
FDA approved Breckenridge Pharmaceutical's original generic duloxetine hydrochloride delayed-release capsules, a generic version of the anti…
-
CLINICAL_TRIALS trial_result · 2014-06-10Clinical Trial Update: Magnetic Seizure Therapy (MST) for the Treatment of Major Depression [Phase 2]
Phase 2 clinical trial of Magnetic Seizure Therapy for major depressive disorder has completed.
-
CLINICAL_TRIALS research · 2014-06-10Clinical Trial Update: Hereditary AngioEdema, Neurobiology and Psychopathology
This clinical trial update from University Hospital, Catania reports research into hereditary angioedema with neurobiological and psychopath…
-
FDA approval · 2014-06-09FDA Approved: DULOXETINE HYDROCHLORIDE — Original Application (Alembic Pharmaceuticals Limited)
FDA approved Alembic Pharmaceuticals Limited's original ANDA for duloxetine hydrochloride, establishing a generic version of duloxetine.
-
CLINICAL_TRIALS trial_result · 2014-06-09Clinical Trial Update: SSRI Administration to Reduce Acute Stress Disorder Symptoms and Prevent Depression and PTSD in Physical Trauma Victims [Phase 3]
A Phase 3 trial evaluating SSRI administration to reduce acute stress disorder symptoms and prevent depression and post-traumatic stress dis…
-
CLINICAL_TRIALS trial_result · 2014-06-06Clinical Trial Update: Light, Ion, and Fluoxetine Efficacy (LIFE) in Depression [Phase 3]
Phase 3 LIFE trial evaluating light therapy, Ion therapy, and fluoxetine for major depressive disorder has completed.
-
CLINICAL_TRIALS research · 2014-06-06Clinical Trial Update: Mental Health Assessment Project on the Thailand-Burma Border [NA]
Clinical trial update on a mental health assessment project among populations along the Thailand-Burma border; study related to depression, …
-
CLINICAL_TRIALS trial_result · 2014-06-05Clinical Trial Update: Cognitive Therapy for Recurrent Depression [Phase 3]
Phase 3 trial evaluating cognitive therapy for recurrent major depressive disorder has completed; results were posted in 2014.